Clinical trials demonstrated that d-serine administration improves schizophrenia symptoms,
raising the possibility that altered levels of endogenous d-serine may contribute to the N …

Background The hypofunction of theN-methyl-D-aspartate (NMDA) subtype of glutamate
receptors has been implicated in the pathophysiology of schizophrenia. Several lines of …

Several lines of evidence suggest that d-serine, an endogenous agonist of the glycine site
on the NMDA receptors, might play a role in the pathophysiology of schizophrenia. The …

Changes in D-serine availability in the brain may contribute to the hypofunction of NMDA-
glutamate receptors in schizophrenia; however, measurements of blood levels of D-serine in …

D-Serine is a potent co-agonist at the NMDA glutamate receptor and has been the object of
many preclinical studies to ascertain the nature of its metabolism, its regional and cellular …

An increasing amount of evidence indicates that d-serine, a potent and selective
endogenous coagonist of the N-methyl-d-aspartate receptor (NMDAR), is efficacious in the …

Background: Hypofunction of N-methyl-D-aspartate (NMDA) subtype glutamate receptor has
been implicated in the pathophysiology of schizophrenia. D-serine is a full agonist of the …

BACKGROUND: D-serine is an allosteric modulator of the brain N-methyl-d-aspartate
(NMDA) receptor and a potential novel treatment of schizophrenia. Double-blind studies …

The glutamate neurotransmitter system is one of the major candidate pathways for the
pathophysiology of schizophrenia, and increased understanding of the pharmacology …

The N‐methyl‐d‐aspartate receptor co‐agonist d‐serine is synthesized by serine racemase
and degraded by d‐amino acid oxidase. Both d‐serine and its metabolizing enzymes are …